DNL.L (Mkap €25 M) Attraktive Medikamente vor der Zulassung (Seite 10)

[Stoxtrayder]

Letzte Woche hatte btw Futura Medical auch eine EMA-Zulassung erhalten. Montags drauf stieg der Kurs (durch Presse-Coverage etc.) nochmals um knappe 50%. Ich denke, daß es nicht mehr lange Diurnal-Anteile unter 100 Pence gibt...

[watchingtheflood]

Und wieder mal ein Grund, unserem lieben BIOHERO einen Dank auszusprechen für sein unermüdliches Gründeln in den Biotech-Gewässern....👍

[Stoxtrayder]

Hat vorhin fast sogar schonmal an die 100 Pence-Marke angeklopft. Werde weiterhin halten, mal schauen wo die Reise hingeht. 1% Depotgewichtung mit EK 40 Pence macht das Kraut nicht fett. 😉

Bei 150 Pence schaut‘s schon anders aus, da setz ich mal mein persönliches Kursziel. Diurnal hat ein Alleinstellungsmerkmal auch wenn dee Markt nicht sooo rießig ist. Die Ditest-Geschichte ist dagegen der größere Markt...😏

[Stoxtrayder]

Aha, hab ich‘s mir doch gedacht...

Diurnal Group PLC 26 March 2021 26 March 2021 Diurnal Group plc ("Diurnal" or the "Company") European Medicine Agency issues positive opinion for Diurnal's second product in Europe In preparation for commercial product launch in Europe, Chronocort(R) to be branded as Efmody(R) Commercial launch anticipated in Q3 2021 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has issued a positive opinion to the European Commission recommending Efmody(R) (hydrocortisone modified-release hard capsules - development name Chronocort(R) ) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The formal approval of marketing authorisation from the European Commission is anticipated in June 2021, in accordance with the 67-day timeline following the adoption of the positive opinion by the CHMP, together with a decision on grant of Orphan Drug Status. To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021. The Company intends to mirror its strategy for Alkindi(R) (hydrocortisone granules in capsules for opening) by commercialising the product itself in core European markets. Efmody(R) is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect a total of approximately 41,000 patients in Europe. Martin Whitaker, Chief Executive Officer of Diurnal, commented: "We are delighted that the CHMP endorses Efmody(R) as a treatment option for adult and adolescent patients suffering from congenital adrenal hyperplasia. We look forward to expanding our commercial portfolio with the planned launch of Efmody(R) across Europe alongside our first product Alkindi(R) , to provide life-long treatment for patients with congenital adrenal hyperplasia, enabling Diurnal to continue to drive towards becoming a world-leading specialty endocrinology business." This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR). For further information, please visit www.diurnal.co.uk or contact: [phone] Diurnal Group plc 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Panmure Gordon (UK) Limited (Nominated Adviser [phone] and Sole Broker) 2500 Corporate Finance: Freddy Crossley, Emma Earl Corporate Broking: Rupert Dearden [phone] FTI Consulting (Media and Investor Relations) 1000 Simon Conway Victoria Foster Mitchell Notes to Editors About Congenital Adrenal Hyperplasia

[2brix]

denke ich auch.
was habt ihr so für Kursziele wenn news kommt?

[Stoxtrayder]

Ich denke, da ist was durchgesickert bzgl. EMA...

[Stoxtrayder]

Ausbruch über die 80-Pence-Marke gerade 💪

[Jack48]

Ja, nach der hoffentlich positiven Rückmeldung der EMA, bis spätestens nächste Woche, sollte es nochmal einen Schub geben. Anschließend bin ich wieder raus. Q1 wurde heute übrigens nochmal vom Management bestätigt.
https://www.diurnal.com/Investor/news/chronocort-r-distribut…

[Stoxtrayder]

Macht sich gut die Tage über 👌

52-Wochen, vom September 2020, ist in Reichweite...

Bin hier immernoch, seit Biohero’s Empfehlung mit einer Mini-Position an Board, mal schauen wo die Reise hingeht... 😉

[Sugar2000]

https://www.edisongroup.com/publication/improving-treatments…

Kursziel 144 pence